Shares of Bio-Rad Laboratories Inc. (NYSE:BIO) saw strong trading volume on Monday . 78,718 shares traded hands during mid-day trading, a decline of 15% from the previous session’s volume of 92,240 shares.The stock last traded at $142.60 and had previously closed at $142.99.

A number of analysts have recently commented on the stock. Jefferies Group reissued a “buy” rating on shares of Bio-Rad Laboratories in a research report on Wednesday, June 8th. Zacks Investment Research raised shares of Bio-Rad Laboratories from a “sell” rating to a “hold” rating in a research report on Wednesday, April 27th.

The stock has a market cap of $4.21 billion and a PE ratio of 39.17. The stock has a 50 day moving average of $143.41 and a 200-day moving average of $137.93.

Bio-Rad Laboratories (NYSE:BIO) last issued its earnings results on Thursday, May 5th. The company reported $0.42 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.60 by $0.18. During the same period in the previous year, the business posted $0.61 earnings per share. The business earned $471.20 million during the quarter, compared to analyst estimates of $463.90 million. The firm’s quarterly revenue was down .3% compared to the same quarter last year. On average, equities research analysts anticipate that Bio-Rad Laboratories Inc. will post $3.31 EPS for the current fiscal year.

A number of large investors have recently modified their holdings of the stock. Sei Investments Co. raised its stake in shares of Bio-Rad Laboratories by 3.5% in the fourth quarter. Sei Investments Co. now owns 19,099 shares of the company’s stock worth $2,648,000 after buying an additional 642 shares during the period. Comerica Bank raised its stake in shares of Bio-Rad Laboratories by 0.3% in the fourth quarter. Comerica Bank now owns 15,009 shares of the company’s stock worth $1,959,000 after buying an additional 38 shares during the period. Bank of Montreal Can raised its stake in shares of Bio-Rad Laboratories by 13.1% in the fourth quarter. Bank of Montreal Can now owns 10,021 shares of the company’s stock worth $1,390,000 after buying an additional 1,163 shares during the period. Levin Capital Strategies L.P. raised its stake in shares of Bio-Rad Laboratories by 9.5% in the fourth quarter. Levin Capital Strategies L.P. now owns 689,214 shares of the company’s stock worth $95,566,000 after buying an additional 60,059 shares during the period. Finally, Morgan Stanley raised its stake in shares of Bio-Rad Laboratories by 356.6% in the fourth quarter. Morgan Stanley now owns 71,554 shares of the company’s stock worth $9,921,000 after buying an additional 55,884 shares during the period.

Bio-Rad Laboratories, Inc (Bio-Rad) manufactures and supplies products and systems used for the life science research, healthcare, analytical chemistry and other markets. The Company offers products to separate complex chemical and biological materials, and to identify, analyze and purify their components.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.